Methyl-1-etiocholenolol-epietiocholanolone

Synopsis

Methyl-1-Etiocholenolol-Epietiocholanolone: A Comprehensive Reference

1. Identity, Nomenclature, and Chemical Character

Names and Synonyms

Methyl-1-Etiocholenolol-Epietiocholanolone is the active compound ingredient contained in the prohormone products known commercially as Methyl-1-Alpha (M1A) and Methyl-1-AD. The compound is also sold under the brand names Alpha One, Alpha-M1, Methyl XT, and Alpha-1 MAX, among others. Its synonyms include Alpha One, Methyl-1-Alpha, Methyl 1-AD, and the chemical descriptor 17a-methyl-1-androstene-3b,17b-diol.

The name "Methyl-1-Etiocholenolol-Epietiocholanolone" is a composite term that has caused considerable confusion. Inspecting the strange nomenclature, one may suspect two separate compounds: Methyl-1-Etiocholenolol and, separately, Epietiocholanolone. The term "etiocholane" is synonymous with 5β-androstane, used to denote a 19-carbon steroid structure.

Chemical Structure

The Methyl-1-etiocholenolol component has the IUPAC name (3β,5α,17β)-17-methyl-androst-1-ene-3,17-diol, a molecular formula of C₂₀H₃₂O₂, and a molecular weight of 304.47 g/mol. The compound features eight defined stereocenters. Its structure includes a methyl group at the 17α position, a modification that enhances oral bioavailability by reducing first-pass hepatic metabolism.

The core skeleton is an androstane derivative with a 1-en-3-ol moiety, with key modifications comprising a 17α-methyl group and hydroxyl groups at C3 and C17.

Methyl-1-Etiocholenolol-Epietiocholanolone is most likely a 17-alpha alkylated steroid, consistent with the prefix "methyl" and current naming trends for designer steroids.

The "Epietiocholanolone" component of the name refers to a distinct but related molecule. Epietiocholanolone is another name for epi-5-beta androsterone — an androstane with a hydroxyl at the 3 position and a ketone at the 17 position. This compound requires a two-step conversion to become an active androgen. The 17-keto group converts to a 17-hydroxyl via 17β-Hydroxysteroid dehydrogenase, and the 3-hydroxy is converted to a ketone via 3β-HSD, ultimately converting to the 5-alpha reduced androgen dihydrotestosterone (DHT).

A widely-cited but unconfirmed claim in bodybuilding communities is that the compound may be 7α-Methylandrost-1-ene-3β-ol-17-one — essentially androsterone with a double bond at the 1 position and a methyl group at the 7 position. The precise identity of the compound in finished products has historically been ambiguous.

Source and Natural Status

Methyl-1-Etiocholenolol-Epietiocholanolone is a synthetic derivative related to the class of androstane steroids. It has no botanical or food-based source. It is entirely a product of laboratory synthesis, structurally derived from naturally occurring endogenous steroid metabolites — chiefly etiocholanolone and related androstane structures — but does not occur in any natural botanical or animal product in its methylated, modified form.

Etiocholanolone itself — the parent endogenous compound — is also known as 5β-androsterone, or 3α-hydroxy-5β-androstan-17-one, an etiocholane (5β-androstane) steroid and an endogenous 17-ketosteroid that is produced from the metabolism of testosterone.

Common Forms and Preparations

Methyl-1-Etiocholenolol-Epietiocholanolone has been sold exclusively in oral dosage forms, most commonly capsules and tablets. It was originally introduced to the market in approximately 2009 under the brand name Alpha One. As of the most recent information, only three official prohormone products contained this compound, and all have had their production discontinued: Alpha One by Competitive Edge Labs, Methyl-1-Alpha by Legal Gear (LG Sciences), and Methyl XT by EST.

2. Historical and Commercial Context

Origins in the Designer Steroid Era

Methyl-1-Etiocholenolol-Epietiocholanolone has no traditional medicinal history and is not referenced in any classical pharmacopeial or ethnobotanical tradition. Its development belongs entirely to the modern era of designer steroid chemistry.

Compounds in the etiocholanolone family attracted attention due to their structural similarity to endogenous hormones, leading to speculation regarding potential anabolic or ergogenic effects. While traditional use is limited due to the relatively recent introduction of such designer steroids, their inclusion in supplements reflects ongoing interest in maximizing physical conditioning and recovery.

The compound emerged directly from the regulatory landscape created by U.S. prohormone legislation. When the first ban occurred in 2004, supplement companies simply replaced the prohormones with other compounds that were similar in structure but not on the banned list. Methyl-1-Etiocholenolol-Epietiocholanolone was one of a series of such post-ban replacement compounds.

The related precursor, Methyl-1-Testosterone (M1T), has a longer documented research history. Methyl-1-testosterone was first researched in 1962 during an extremely active time for steroid research. M1T had a very favorable ratio of anabolic to androgenic effect, so there was much promise with this compound. But like many other steroids being studied at that time, it was not selected to be developed as a medicine. M1T reemerged in 2003 when it was introduced as a "dietary supplement" in the United States. Since it was relatively unknown, it was not specifically listed in the 1991 law controlling anabolic steroids.

Since 1994, with the passing of the U.S. Dietary Supplement and Health Education Act (DSHEA), many new dietary supplements became available on the market, and more and more products appeared containing steroids that had never been marketed as approved pharmaceuticals.

Regulatory History and Current Legal Status

In December 2014, President Barack Obama signed the Designer Anabolic Steroid Control Act of 2014 (DASCA), which replaced two prior versions of the Anabolic Steroid Control Act (ASCA) passed in 1990 and 2004, respectively. Congress intended the DASCA to erase the distinction between the substances once called "prohormones" — steroidal substances unlawfully marketed as dietary supplement products that were either precursors of traditional anabolic steroids or steroidal substances not specially listed in the prior ASCA — and substances traditionally regarded as anabolic steroids such as testosterone, nandrolone, and trenbolone.

The DASCA provides that a drug or hormonal substance that is not listed but is derived from, or has a chemical structure substantially similar to, an anabolic steroid shall be considered to be an anabolic steroid if it has been created or manufactured with the intent of producing a substance that either promotes muscle growth or otherwise causes a pharmacological effect similar to that of testosterone, or has been or is intended to be promoted in any manner suggesting it will promote any pharmacological effect similar to that of testosterone.

Methyl-1-etiocholenolol is classified as a Schedule III controlled substance under the U.S. Controlled Substances Act and is prohibited by the World Anti-Doping Agency (WADA). Methyl-1-Alpha is an illegal prohormone (banned) in the United States.

In February 2006, Health Canada warned consumers not to use M1T-containing products because of potentially serious health risks such as liver disorders and hardening of the arteries.

3. The Etiocholanolone Parent Compound: Background Science

To understand Methyl-1-Etiocholenolol-Epietiocholanolone, familiarity with its parent steroid metabolite, etiocholanolone, is essential. The metabolic end products of testosterone and androstanedione that appear in the urine are androsterone and etiocholanolone. These substances have slight or no androgenic activity.

Etiocholanolone is known to be an inhibitory androstane neurosteroid, acting as a positive allosteric modulator of the GABA-A receptor, and possesses anticonvulsant effects. It causes fever, immunostimulation, and leukocytosis, and has been used to evaluate adrenal cortex function, bone marrow performance, and in neoplastic disease to stimulate the immune system.

In 1956, Kappas, Hellman, Fukushima, and Gallagher first reported that the steroid metabolite etiocholanolone caused fever when it was administered to man. Subsequent work substantiated the pyrogenic properties of etiocholanolone and other 5β-H C19, C21, and C24 steroids. These observations were especially noteworthy since they describe biologic activity possessed by a class of compounds previously thought to be physiologically inert and represent the first discovery of pyrogenic substances of endogenous origin in man.

Evidence for a relationship between elevated levels of unconjugated etiocholanolone in the plasma and fever in some clinical syndromes has accumulated. In some patients with adrenogenital syndromes, familial Mediterranean fever, granuloma, anoxic anencephaly, adrenal cortical carcinoma, and cirrhosis of the liver, the etiocholanolone concentration in the plasma seems to correlate with the occurrence of otherwise unexplained fevers.

Studies have shown that steroids nonpyrogenic in man, such as androsterone and 3β-OH etiocholanolone, are also nonpyrogenic in vitro. The pyrogenic action of steroids appears to be confined to humans, distinguishing it from bacterial pyrogens. The synthetic derivative Methyl-1-Etiocholenolol-Epietiocholanolone is structurally remote from the etiocholanolone that exhibits these pyrogenic effects and is designed primarily for its androgen receptor activity, not for pyrogenic or immunostimulatory properties.

4. Key Constituents and Active Compounds

Dual Activity: Direct and Precursor-Mediated

Methyl-1-Etiocholenolol-Epietiocholanolone is an active oral steroid that has a conversion rate of approximately 15–20% into the powerful M1T (Methyl-1-Testosterone) prohormone. It is a methylated prohormone. Critically, this compound converts to Methyl-1-Testosterone (M1T) at about 15–20%, and in addition, M1A is already an active oral steroid, which makes Alpha One a very potent prohormone.

Reliable information on the precise conversion rate to M1T is limited, and Methyl 1-AD is already an active anabolic in its own right; regardless of the conversion to M1T, its direct activity is quite sufficient.

Mechanism of Action: Androgen Receptor Binding

Methyl-1-etiocholenolol binds selectively to androgen receptors (AR) in muscle tissue, activating transcriptional pathways that increase protein synthesis and nitrogen retention. Unlike testosterone, it shows minimal affinity for sex hormone-binding globulin (SHBG), enhancing its free fraction in circulation.

The closely related conversion product, M1T, provides further mechanistic insight. The designer steroid methyl-1-testosterone (M1T) was identified and its biological activity, potential adverse effects, and metabolism were investigated. The affinity of M1T toward the androgen receptor was tested in vitro using a yeast AR transactivation assay. In the yeast AR transactivation assay, M1T was characterized as a potent androgen. In rats, M1T dose-dependently stimulated prostate and levator ani muscle weight after subcutaneous administration.

M1T exhibits high affinity for the androgen receptor, promoting dose-dependent anabolic effects such as increased levator ani muscle weight and prostate proliferation in animal models, alongside strong androgenic activity without selective modulator properties. In rodent models via the Hershberger assay, M1T's exceptional potency was demonstrated, with subcutaneous administration leading to dose-dependent increases in levator ani muscle weight (a marker of anabolic activity) and ventral prostate weight (a marker of androgenic activity), indicating strong anabolic and androgenic activity that surpasses the profile of testosterone.

Regarding tissue selectivity, M1T exhibits robust anabolic effects in muscle while also exerting considerable androgenic influence in the prostate, without the dissociative properties characteristic of selective androgen receptor modulators (SARMs).

Metabolic Resistance and Oral Bioavailability

Methyl-1-etiocholenolol exhibits metabolic resistance due to its 17α-methyl group, which impedes hepatic degradation. In human studies, the compound is excreted predominantly unchanged in urine, with minor metabolites identified as dehydrometabolites. These metabolites are detectable via gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).

In particular, 17α-alkylated anabolic androgenic steroids appear to be hepatotoxic, whereas nonalkylated AAS appear not to be. The 17α-alkyl substitution retards hepatic metabolism of the AAS, rendering it orally bioavailable.

For the M1T metabolite in humans: M1T was confirmed in urine in addition to its main metabolites 17α-methyl-5α-androst-1-ene-3α,17β-diol and 17α-methyl-5α-androstane-3α,17β-diol. Additionally, the corresponding 17-epimers as well as 17β-hydroxymethyl-17α-methyl-18-nor-5α-androsta-1,13-dien-3-one and its 17-epimer were detected, and their elimination kinetics were monitored.

Aromatization Profile

Alpha One (Methyl-1-Etiocholenolol-Epietiocholanolone) is reported to promote increased lean muscle mass, dense muscle gains, and strength gains, and to have no estrogen conversion. This is consistent with the profile of M1T, which is a DHT derivative and cannot convert to DHT or estrogen. Despite the lack of aromatization, gynecomastia reports have occasionally appeared in user communities.

Anti-Doping Detection

Anti-doping laboratories employ advanced techniques to identify methyl-1-etiocholenolol and its metabolites: GC-MS targets the underivatized parent compound, and LC-MS/MS detects dehydrometabolites. Manufacturers often market the compound under misleading names (e.g., "epietiocholanolone") to circumvent regulations. Its structural similarity to endogenous steroids complicates detection, necessitating high-resolution mass spectrometry.

5. Scientific Evidence by Area of Use

5a. Skeletal Muscle Anabolism and Strength

Claimed use: Enhancement of lean muscle mass and muscular strength in athletes and bodybuilders.

Human/clinical evidence: From a scientific standpoint, the validation of Methyl-1-Etiocholenolol-Epietiocholanolone's efficacy remains preliminary. Currently, there is a lack of robust, peer-reviewed clinical studies directly evaluating this compound in humans. No published randomized controlled trials (RCTs) evaluating this specific compound in human subjects were identified in a search of the peer-reviewed literature.

Evidence for the anabolic effects of the compound rests almost entirely on:

Animal model data from the related conversion product M1T: In rats, M1T dose-dependently stimulated prostate and levator ani muscle weight after subcutaneous administration. Oral administration modulated IGF-I and AR expression in the gastrocnemius muscle in a dose-dependent manner.
In vitro androgen receptor data: In the yeast AR transactivation assay, M1T was characterized as a potent androgen.
User-reported outcomes: These are anecdotal, uncontrolled, and subject to substantial confounders (diet, training, other compounds used).

Evidence strength: For Methyl-1-Etiocholenolol-Epietiocholanolone itself, there are no peer-reviewed human clinical trials. The mechanistic plausibility of anabolic activity is supported by in vitro and animal data on structurally related compounds (primarily M1T), but extrapolation to this specific compound is speculative. The overall evidence for clinical efficacy in humans is classified as absent/unverified.

5b. Body Composition (Bulking)

Fluid retention is reportedly very common, so most users choose to use this compound on a diet intended strictly for bulking. The molecular mechanism underlying fluid retention with 17α-alkylated anabolic steroids is consistent with androgen-mediated sodium and water retention, a class effect documented for multiple AAS in clinical literature, but no specific study on this compound's effect on body composition markers has been published.

5c. Potential Prohormone Conversion Pathway

Its effect can be manifested directly or by 15–20% conversion to the theoretically more powerful Methyl-1-testosterone (M1T), a methylated testosterone derivative characterized by a very high anabolic-to-androgenic ratio. The magnitude of this conversion in living humans has not been formally quantified in peer-reviewed research specific to this prohormone.

M1T is advertised to be highly anabolic and moderately androgenic and not convertible to estrogens. However, in scientific literature, it was reported to show anabolic properties of 25% and androgenic properties of 50% compared with testosterone propionate after intramuscular injection in castrated rats. This discrepancy between marketed claims and laboratory findings is notable.

6. Body Systems and Health Areas Associated With This Compound

6a. Musculoskeletal System

The compound's primary intended effect is on skeletal muscle via androgen receptor activation. Anabolic steroids increase protein within cells, especially in skeletal muscles. The American College of Sports Medicine acknowledges that anabolic-androgenic steroids, in the presence of adequate diet, can contribute to increases in body weight, often as lean mass increases, and that the gains in muscular strength achieved through high-intensity exercise and proper diet can be additionally increased by the use of AAS in some individuals. These general class-level findings are not specific to Methyl-1-Etiocholenolol-Epietiocholanolone.

6b. Hepatic System (Liver)

AAS abuse can cause adverse effects, among which are hepatotoxic effects. These effects include cholestatic icterus and possibly peliosis hepatis and hepatocellular carcinoma or adenoma. The mechanism responsible for the hepatotoxicity induced by 17α-alkylated AAS remains poorly understood. However, oxidative stress has been repeatedly shown to be associated with it.

A clinically documented case report specifically identifies this compound as a cause of serious liver injury. A 26-year-old previously healthy man presented with a three-week history of worsening jaundice, pruritus, clay-colored stools, and dark urine. The patient had started taking a bodybuilding supplement identified as Methyl-1-Etiocholenolol-Epietiocholanolone, a prohormone/anabolic designer steroid, two months prior to presentation. He reported no other medications and no tobacco, illicit drug, or alcohol use. Examination revealed diffuse jaundice and scleral icterus. Hepatic function panel revealed AST 67 U/L, ALT 106 U/L, alkaline phosphatase 166 U/L, and total bilirubin 32.5 mg/dL.

Hepatic adverse effects are classically associated with 17α-alkylated AAS due to their ability to bypass first-pass hepatic metabolism. Orally administered 17α-alkylated steroids are considered the most hepatotoxic. They increase the number of reactive oxygen species (ROS), which directly injure liver tissue. This may be manifested as an elevation of liver enzymes, peliosis hepatis, or distinctive acute cholestasis.

While 17α-alkylated AAS-induced hepatotoxicity has been observed in multiple controlled clinical trials, it has not been observed for non-17α-alkylated AAS, not even with supraphysiological dosages (up to 600 mg weekly) of testosterone.

6c. Endocrine / Reproductive System

Prolonged exposure to supraphysiological doses of exogenous testosterone or synthetic anabolic-androgenic steroids is associated with marked suppression of the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback mechanisms that inhibit gonadotropin secretion. Elevated androgen and estradiol concentrations reduce GnRH pulsatility at the hypothalamic level and suppress LH and FSH release from the anterior pituitary.

These changes result in reduced intratesticular testosterone concentrations, testicular atrophy, and impaired spermatogenesis. Cessation of AAS use does not invariably lead to full recovery of endocrine function. Observational studies indicate that subnormal serum testosterone levels and clinical features of androgen deficiency may persist for months or even years following withdrawal.

Dose-dependent suppression of the hypothalamic-pituitary-gonadal (HPG) axis is documented for this class of 17α-alkylated compounds.

6d. Cardiovascular System

Lipid profile changes associated with this class of compounds include reductions in HDL cholesterol (reported as −20 to −30%) and increases in LDL cholesterol (reported as +15–20%). These figures derive from chemical vendor documentation and have not been independently verified in published clinical trials specific to this compound. As a class effect, AAS have reported toxicological effects on the cardiovascular, hepatic, and neuro-endocrine systems.

6e. Androgenic Tissues (Skin, Hair, Prostate)

Because Methyl-1-Etiocholenolol-Epietiocholanolone is not a selective androgen receptor modulator, its androgenic effects in non-muscular tissues are expected based on class-level data. M1T exhibits robust anabolic effects in muscle while also exerting considerable androgenic influence in the prostate, without the dissociative properties characteristic of SARMs. User-reported side effects consistent with androgenic activity include acne and hair loss, though no controlled data specific to this compound document the incidence of these effects.

7. Dosage and Administration

Reported Dosages

The following dosage information derives from the available sources and does not represent clinical recommendations:

A recommended dosage of 20–40 mg per day is listed, with an average cycle length of 3–4 weeks.
A twice-daily 20 mg dose (totaling 40 mg/day) is recommended by some sources, with a 4–8 week cycle advised and 8 weeks between cycles.
Some sources specify keeping cycles "very short, with three to four weeks being the most common cycle length."

Due to its potency, this compound is described as being used only for brief periods of time, much more brief than most commonly used steroid supplements.

Important context: None of these dosage ranges derive from controlled human clinical trials. They originate from supplement company labeling and community-based usage reports. The compound is a controlled substance in the United States, and no FDA-approved therapeutic dosage exists.

Dosage Form

This compound is classified as methylated. It is formulated as oral capsules or tablets. The oral route is the only documented route of human administration for this compound in the supplement context.

8. Safety Considerations and Known Interactions

8a. Hepatotoxicity

This is the most clinically substantiated safety concern. A published case report documents a 26-year-old man developing worsening jaundice, pruritus, clay-colored stools, and dark urine after two months of taking a bodybuilding supplement identified as Methyl-1-Etiocholenolol-Epietiocholanolone. This individual case, published in a peer-reviewed gastroenterology journal, is the most direct clinical evidence of hepatic injury attributable to this compound.

The hepatic injury from 17α-alkylated AAS may be manifested as an elevation of liver enzymes, peliosis hepatis, or distinctive acute cholestasis. Furthermore, AAS abuse for a prolonged period of time may induce the growth of hepatocellular adenoma and hepatocellular cancer.

Historical reporting of hepatotoxicity from AAS may be overestimated due to the association of bodybuilding and strength training with elevations in ALT and AST independent of AAS use.

Elevated liver enzymes (ALT/AST) due to 17α-methylation are a recognized effect of this class of compound.

8b. Endocrine Suppression and Post-Cycle Recovery

Cessation of AAS use does not invariably lead to full recovery of endocrine function. Observational studies indicate that subnormal serum testosterone levels and clinical features of androgen deficiency may persist for months or even years following withdrawal. This risk applies to Methyl-1-Etiocholenolol-Epietiocholanolone as a potent androgen receptor agonist.

8c. Cardiovascular Effects

Reductions in HDL cholesterol and increases in LDL cholesterol are documented for 17α-alkylated androgens as a class. These lipid changes are associated with increased cardiovascular risk in longer-term use, consistent with what has been published for related 17α-alkylated AAS.

8d. Blood Pressure

Methyl-1-etiocholenolol-epietiocholanolone is methylated and carries potentially harsh side effects such as issues with blood pressure, excessive stress on liver function, and gynecomastia. Blood pressure elevation associated with AAS use has been documented at the class level, related to fluid retention, increased red cell mass, and direct vascular effects.

8e. Potential for Permanent Endocrine Damage

Failure to monitor and carefully regulate the use of methyl-1-etiocholenolol-epietiocholanolone can result in permanent damage to the body and the way it naturally produces hormones. This claim, while originating from a non-academic source, is consistent with peer-reviewed documentation of prolonged HPG axis suppression following AAS use. While short-term or single-cycle AAS use is often followed by partial or complete restoration of HPG axis function, prolonged or repeated exposure to supraphysiological doses is associated with an increased risk of persistent dysfunction.

8f. Drug Interactions and Stacking Risks

No peer-reviewed pharmacokinetic interaction studies for Methyl-1-Etiocholenolol-Epietiocholanolone have been published. At the class level, hepatotoxicity risk is substantially amplified by concurrent use of other 17α-alkylated orally active anabolic steroids. Community documentation and user reports strongly caution against concurrent use of multiple methylated compounds. The case report above specifically noted the patient was taking no other medications, establishing this compound as a sole causative agent in the documented case of severe liver injury.

8g. Anti-Doping Status

Anabolic androgenic steroids are prohibited as doping substances in sports by the World Anti-Doping Agency. Methyl-1-etiocholenolol is classified as a Schedule III controlled substance under the U.S. Controlled Substances Act and is prohibited by WADA. Any competitive athlete subject to anti-doping rules who uses this compound risks disqualification and sanction.

9. State of the Evidence: Overall Assessment

From a scientific standpoint, the validation of Methyl-1-Etiocholenolol-Epietiocholanolone's efficacy remains preliminary. Currently, there is a lack of robust, peer-reviewed clinical studies directly evaluating this compound in humans.

The compound's putative anabolic mechanisms are plausible — androgen receptor binding, promotion of protein synthesis, and nitrogen retention — based on in vitro work and animal models involving the structurally related conversion product M1T. However, the compound itself has not been the subject of any published randomized controlled trial, prospective cohort study, or formally designed pharmacological investigation in human subjects. The sole human-specific peer-reviewed documentation identified is a case report describing serious hepatotoxicity. All claims of efficacy originate from commercial materials, supplement community forums, and anecdotal reports.

Health risks can be produced by long-term use or excessive doses of anabolic steroids. For this particular compound, both short-term hepatic injury (documented in case literature) and longer-term hormonal disruption (documented at the AAS class level) represent the most evidence-supported safety concerns.